At-Home Prescription Drug Disposal System

目的：展示一种安全、即时、成本效益、生态和用户友好的系统的有效性，该系统能够在家中停用和处置精神活性处方药。吉纳公司建议开发一种小型电解混合氧化剂(MOX)系统，以安全地销毁固体、液体或贴片形式的精神活性药物。拟议的系统被设计为临时安装在标准家用水龙头上，以消除对额外设备的需求，并实现比现有技术更大的尺寸、性能和安全优势。第一阶段将评估概念的总体可行性，重点是MOX反应堆的设计和确定使高使用率的药物失效的要求。第一阶段侧重于以下具体目标： 1.设计、制造和组装BDD/MOX系统组件。通过设计电极结构和组装必要的部件，专注于紧凑型和功能性电解MOX反应器单元的开发/制造。 2.确定关键工艺变量和参数的特征。将确定和优化工艺变量和参数，以充分发电混合氧化剂，以使选定的制药产品失活。 3.在精选药品上演示该系统的适当性能。建议系统的性能将使用根据处方频率、治疗类别和化学结构范围选择的精神活性药物产品(维柯丁、Xanax和左洛复)进行评估。 4.产品使用、放置和安全评估。在整个停用过程中，对产品的易操作性和目标用户安全进行评估，使其免受有害暴露。AIM还将评估向消费者分销产品的不同方式。 5.二期样机初步设计。重点设计第二阶段的设备原型和产品成本分析，以论证拟议的第二阶段扩大失活设备的可行性。

Objective: Demonstrate effectiveness of a safe, immediate, cost-effective, ecological, and user-friendly system that enables at-home deactivation and disposal of psychoactive prescription pharmaceuticals. Giner, Inc. proposes to develop a miniaturized electrolytic mixed-oxidant (MOX) system to safely destroy psychoactive pharmaceuticals in solid, liquid or patch form. The proposed system is designed to temporarily attach to a standard household faucet to eliminate need for extra equipment and to achieve size, performance and safety advantages over existing technologies. Phase I will assess overall feasibility of concept by focusing on design of MOX reactor and identifying requirements to inactivate selection of highly used pharmaceutical drugs. Phase I focus on following Specific Aims: 1. Design, Fabricate and Assemble BDD/MOX System Components. Focus on development/fabrication of compact and functional electrolytic MOX reactor unit by designing electrode structure and assembling necessary components. 2. Characterize Key Process Variables and Parameters. Process variables and parameters will be identified and optimized for sufficient electro-generation of mixed oxidants to inactivate select pharmaceutical products. 3. Demonstrate Suitable Performance of the System on Select Pharmaceuticals. Performance of proposed system will be assessed using psychoactive pharmaceutical products (Vicodin, Xanax, and Zoloft) selected for their frequency of prescription, treatment class and range of chemical structures. 4. Product Use, Placement, and Safety Evaluation. Product evaluated for ease of operation and target user safety from harmful exposure throughout entire deactivation process. Aim will also assess different ways product will be distributed to consumers. 5. Preliminary Design for Phase II Prototype. Focus on designing device prototype for Phase II and product cost analyses to demonstrate feasibility of proposed deactivation device for Phase II scale-up.